-
Loading metrics
Open Access
Peer-reviewed
Research Article
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
-
Ema T. Crooks,
Affiliation San Diego Biomedical Research Institute, San Diego, California, United States of America
⨯ -
Tommy Tong,
Affiliation San Diego Biomedical Research Institute, San Diego, California, United States of America
⨯ -
Bimal Chakrabarti,
Current address: International AIDS Vaccine Initiative HIV Vaccine Design Program, Translational Health Science and Technology Institute, Haryana, India
Affiliation International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center at The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America
⨯ -
Kristin Narayan,
Current address: Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, United States of America
Affiliation Altravax, Inc., Sunnyvale, California, United States of America
⨯ -
Ivelin S. Georgiev,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
Sergey Menis,
Affiliations International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center at The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America
⨯ -
Xiaoxing Huang,
Affiliation National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang District, Beijing, China
⨯ -
Daniel Kulp,
Affiliations International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center at The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America
⨯ -
Keiko Osawa,
Affiliation San Diego Biomedical Research Institute, San Diego, California, United States of America
⨯ -
Janelle Muranaka,
Affiliation Altravax, Inc., Sunnyvale, California, United States of America
⨯ -
Guillaume Stewart-Jones,
Affiliations Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America, MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom
⨯ -
Joanne Destefano,
Affiliation International AIDS Vaccine Initiative, Design and Development Laboratory, Brooklyn, New York, United States of America
⨯ -
Sijy O’Dell,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
Celia LaBranche,
Affiliation Department of Surgery, Duke University, Duke University Medical Center, Durham, North Carolina, United States of America
⨯ -
James E. Robinson,
Affiliation Tulane National Primate Research Center, Covington, Louisiana, United States of America
⨯ -
David C. Montefiori,
Affiliation Department of Surgery, Duke University, Duke University Medical Center, Durham, North Carolina, United States of America
⨯ -
Krisha McKee,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
Sean X. Du,
Affiliation Altravax, Inc., Sunnyvale, California, United States of America
⨯ -
Nicole Doria-Rose,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
Peter D. Kwong,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
John R. Mascola,
Affiliation Vaccine Research Center, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
⨯ -
Ping Zhu,
Affiliation National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang District, Beijing, China
⨯ -
William R. Schief,
Affiliations International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center at The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America, Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America
⨯ -
Richard T. Wyatt,
Affiliations International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center at The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America
⨯ -
Robert G. Whalen,
Affiliation Altravax, Inc., Sunnyvale, California, United States of America
⨯ - [ ... ],
-
James M. Binley
* E-mail: jbinley@sdbri.org
Affiliation San Diego Biomedical Research Institute, San Diego, California, United States of America
⨯ - [ view all ]
- [ view less ]
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
- Ema T. Crooks,
- Tommy Tong,
- Bimal Chakrabarti,
- Kristin Narayan,
- Ivelin S. Georgiev,
- Sergey Menis,
- Xiaoxing Huang,
- Daniel Kulp,
- Keiko Osawa,
- Janelle Muranaka
- Published: May 29, 2015
- https://doi.org/10.1371/journal.ppat.1004932